Table 2 Concordance between: (a) p53 mutation and p53 IHC staining; (b) p53 IHC persistent staining and p53 IHC strong intensity
From: A population-based study of immunohistochemical detection of p53 alteration in bladder cancer
(a) p53 Mutation | |||||||
|---|---|---|---|---|---|---|---|
(neg) N (%) | (pos) N (%) | Total N | Specificity | Sensitivity | (Pos) (95% CI) predictive value | (Neg) (95% CI) predictive value | |
IHC persistent (>50%) | 0.34 (0.29–0.39) | 0.77 (0.72–0.81) | 0.10 (0.07–0.14) | 0.94 (0.91–0.96) | |||
 + (pos) | 197 (65.9) | 23 (76.7) | 220 | ||||
 − (neg) | 102 (34.1) | 7 (23.3) | 109 | ||||
IHC intensity (3+) | 0.77 (0.72–0.82) | 0.53 (0.48–0.59) | 0.19 (0.15–0.23) | 0.94 (0.92–0.97) | |||
 + (pos) | 69 (23.1) | 16 (53.3) | 85 | ||||
 − (neg) | 230 (76.9) | 14 (46.7) | 244 | ||||
299 (100.0) | 236 (100.0) | 329 (100.0) | |||||
(b) IHC persistent (⩾50%) | |||||||
(neg) N (%) | (pos) N (%) | Total N | Specificity | Sensitivity | (Pos) (95% CI) predictive value | (Neg) (95% CI) predictive value | |
IHC intensity (3+) | 0.83 (0.80–0.87) | 0.29 (0.25–0.34) | 0.78 (0.73–0.82) | 0.37 (0.32–0.42) | |||
 + (pos) | 20 (16.7) | 69 (29.2) | 89 | ||||
 − (neg) | 100 (83.3) | 167 (70.8) | 267 | ||||
120 (100.0) | 236 (100.0) | 356 (100.0) | |||||
